Acquired Methemoglobinemia Observational Registry

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

August 31, 2021

Conditions
Methemoglobinemia, AcquiredMethemoglobinemia
Interventions
DRUG

Methylene Blue

Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care

Trial Locations (32)

10032

New York Methodist, New York

15213

University of Pittsburgh, Pittsburgh

19141

Einstein Medical Center, Philadelphia

21201

University of Maryland, Baltimore

28207

Carolinas Medical Center, Charlotte

33410

Palmetto General, Palm Beach Gardens

33606

Tampa General, Tampa

38104

University of Tennessee Health Science Center, Memphis

44106

University Hospitals, Cleveland

44501

Mercy Health, Youngstown

45267

University of Cincinnati, Cincinnati

46202

IU Health, Indianapolis

48202

Henry Ford Health System, Detroit

48236

St John Medical Center, Detroit

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

55101

HealthPartners Regions, Saint Paul

63110

Washington University, St Louis

66160

University of Kansas Health System, Kansas City

68198

University of Nebraska, Omaha

75390

UT Southwestern, Dallas

77030

Baylor College of Medicine, Houston

Houston Methodist, Houston

90048

Cedars Sinai, Los Angeles

95817

UC Davis Health, Sacramento

97239

Oregon Health & Sciences University, Portland

98195

University of Washington, Seattle

06610

Bridgeport Hospital, Bridgeport

06106

Hartford Hospital, Hartford

02115

Partners Healthcare; Brigham and Women's, Boston

01655

UMass Memorial Medical Center, Worcester

07666

Holy Name Medical Center, Teaneck

All Listed Sponsors
collaborator

Prove pharm

INDUSTRY

lead

Hospital Quality Foundation

OTHER

NCT03542760 - Acquired Methemoglobinemia Observational Registry | Biotech Hunter | Biotech Hunter